Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) Operating Expenses (2023 - 2025)

Mangoceuticals' Operating Expenses history spans 3 years, with the latest figure at $7.6 million for Q3 2025.

  • For Q3 2025, Operating Expenses rose 312.54% year-over-year to $7.6 million; the TTM value through Sep 2025 reached $19.6 million, up 110.92%, while the annual FY2024 figure was $8.4 million, 13.45% down from the prior year.
  • Operating Expenses for Q3 2025 was $7.6 million at Mangoceuticals, up from $5.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $7.6 million in Q3 2025 and bottomed at $1.8 million in Q4 2024.
  • The 3-year median for Operating Expenses is $2.5 million (2024), against an average of $3.3 million.
  • The largest annual shift saw Operating Expenses tumbled 35.15% in 2024 before it soared 312.54% in 2025.
  • A 3-year view of Operating Expenses shows it stood at $2.7 million in 2023, then plummeted by 35.15% to $1.8 million in 2024, then skyrocketed by 332.02% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Operating Expenses are $7.6 million (Q3 2025), $5.4 million (Q2 2025), and $4.9 million (Q1 2025).